Drug main Sun Pharmaceutical Industries on Tuesday mentioned it has launched antiviral drug Favipiravir underneath the model identify ‘FluGuard’ for the remedy of gentle to reasonable instances of COVID-19, at Rs 35 per tablet in India. The shares of FluGuard will probably be accessible in the market from this week, Sun Pharma mentioned in a regulatory submitting.
Favipiravir is the one oral anti-viral remedy accepted in India for the potential remedy of sufferers with gentle to reasonable COVID-19 illness, it added.
“We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden.
This is in line with our continuous efforts to support India’s pandemic response,” Sun Pharma India Business CEO Kirti Ganorkar mentioned.
With over 50,000 COVID-19 instances being reported each day in India, there may be an pressing want to supply extra remedy choices to healthcare professionals, he added.
The firm will work carefully with the federal government and medical neighborhood to make sure availability of FluGuard (Favipiravir 200 mg) to sufferers throughout the nation, Sun Pharma mentioned.
Shares of Sun Pharmaceutical Industries closed at Rs 528.50 per scrip on BSE, up 1.67 per cent from its earlier shut.